CRP and Recurrent lower respiratory tract infections: However, a threshold of EUR 30,000 per QALY (quality-adjusted life-year) was assumed in the economic evaluation of point-of-care C-reactive protein testing in Norwegian patients with lower respiratory tract infections by Oppong et al. [25].